
|Articles|October 15, 2003
New drug developed to treat Fabry's disease
New York-Treatment is now available for Fabry's disease, a lysosomal storage disorder with ophthalmologic findings. In April, the FDA granted Orphan Drug designation for agalsidase beta (Fabrazyme, Genzyme General), an enzyme replacement therapy, for the treatment of this progressive and potentially fatal disease.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dr. Mali’s top 5 predictions in ophthalmology for 2026
2
FDA clears Novaliq’s Investigational New Drug application for NOV05
3
Eye exams could enable earlier detection of systemic disease
4
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
5



























